Hong Young Seon
Department of Medical Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
J Hosp Palliat Care. 2021 Mar 1;24(1):66-68. doi: 10.14475/jhpc.2021.24.1.66.
The World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak to be a pandemic on March 12, 2020. In Korea, there have been 24,027 confirmed cases of COVID-19 and 420 deaths as of October 3, 2020. The clinical spectrum of COVID-19 ranges from asymptomatic infection to death. Cancer care in this pandemic has radically changed. The literature was reviewed. The COVID-19 pandemic has made it urgently necessary to profoundly re-organize cancer patients' care without compromising cancer outcomes. Several important questions in regard to COVID-19 infection in cancer patients have emerged. Are patients with cancer at a higher risk of COVID-19 infection? Are they at an increased risk of mortality and severe illness when infected with COVID-19? Does anticancer treatment affect the course of COVID-19? Based on the existing research, cancer patients with immunosuppression are vulnerable to COVID-19 infection, and cancer patients are more likely to experience severe COVID-19. However, chemotherapy and major surgery do not seem to be predictors of hospitalization or severe disease. Korean background data on patients with cancer and COVID-19 are lacking. Prospective multicenter studies on the outcomes of patients with cancer and COVID-19 should be conducted.
2020年3月12日,世界卫生组织(WHO)宣布2019冠状病毒病(COVID-19)疫情为大流行。截至2020年10月3日,韩国已有24027例COVID-19确诊病例,420人死亡。COVID-19的临床谱涵盖从无症状感染到死亡。这场大流行期间的癌症护理已发生彻底改变。本文对相关文献进行了综述。COVID-19大流行使得在不影响癌症治疗效果的前提下,迫切需要对癌症患者的护理进行深刻的重新组织。关于癌症患者感染COVID-19出现了几个重要问题。癌症患者感染COVID-19的风险更高吗?感染COVID-19后,他们的死亡和重症风险会增加吗?抗癌治疗会影响COVID-19的病程吗?基于现有研究,免疫抑制的癌症患者易感染COVID-19,且癌症患者更易出现重症COVID-19。然而,化疗和大手术似乎并非住院或重症疾病的预测因素。韩国缺乏癌症患者和COVID-19患者的背景数据。应开展关于癌症患者和COVID-19患者治疗结果的前瞻性多中心研究。